Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-11-30
1996-07-02
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31405
Patent
active
055322654
ABSTRACT:
A synthetic inhibitor of matrix metalloproteases, the tripeptide hydroxamate GM 6001, is administered to a patient suffering from an inflammatory disease of the central nervous system wherein the effect is mediated primarily through restoration of the blood-CNS barrier.
REFERENCES:
patent: 5268384 (1993-12-01), Galardy
patent: 5270326 (1993-12-01), Galardy et al.
Gijbels, et al., Gelatinase in the Cerebrospinal Fluid of Patients With Multiple Sclerosis and Other Inflammatory Neurological Disorders, Journal of Neuroimmunology, 41 (1992) 29-34.
Gijbels, et al., Gelatinase B is Present in the Cerebrospinal Fluid During Experimental Autoimmune Encephalomyelitis and Cleaves Myelin Basic Protein, Journal of Neuroscience Research 36:432-440 (1993).
Gijbels, et al., Gelatinase B Producing Cells in Mulitiple Sclerosis Lesions, J. Cell. Biochem. Suppl. 18D:143 (1994).
Grobelny, et al., Inhibition of Human Skin Fibroblast Coolagenase, Thermolysin, and Pseudomonas Aeruginosa Elastase B Peptide Hydroxamic Acids, Biochemistry, vol. 31, No. 31, 76152-54 (1992).
Galardy, et al., Low Molecular Weight Inhibitors in Corneal Ulceration, Annals New York Academy of Sciences, 732:315-323 (1994).
Schultz, et al., Treatment of Alkali-Injured Rabbit Corneas With a Synthetic Inhibitor of Matrix Metalloproteinases, Investigative Ophthalmology & Visual Science, vol. 33, No. 12, 3325-3331 (Nov. 1992).
Galardy, et al., Inhibition of Angiogenesis by the Matrix Metalloprotease Inhibitor N-[2R-2-(Hydroaxamidocarbonymethyl)-4-Methylpentanoyl)]-L-Tryptophan Methylamide, Cancer Research 54, 4715-4718 (Sep. 1, 1994).
Bendeck, et al., Smooth Muscle Cell Migration and Matrix Metalloproteinase Expression After Arterial Injury in the Rat, Circulation Research, vol. 75, No. 3 (Sep. 1994).
Gijbels Koenraad
Steinman Lawrence
Rowland Bertram I.
Sherwood Pamela J.
Spivack Phyllis G.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Treatment of central nervous system inflammatory disease with ma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of central nervous system inflammatory disease with ma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of central nervous system inflammatory disease with ma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1506766